7 Best Peptides for Fertility

What to Know Before Choosing a Peptide for Fertility Support

Fertility is one of the more complex areas of peptide research, and it draws from a wider spectrum of compounds than almost any other goal. Some of the peptides people use here are standard components of clinical IVF protocols, prescribed by reproductive endocrinologists and backed by decades of data. Others are in active clinical trials right now, with Phase 2 results already in hand. And a meaningful number are research-grade compounds that show up constantly in community protocols despite having little or no published human data for fertility specifically. All of them belong in this guide.

A compound earns a spot on this list if people use it for fertility support, or are actively discussing using it for that purpose. That is the only test. FDA approval status, depth of clinical literature, and availability through standard medical channels all shape how each compound is described, but none of them determine whether a compound appears here. A peptide used widely in community protocols with only animal-model data behind it is described honestly, and it stays on the list.

The compounds below are numbered, and those numbers represent an ordering by prominence in the research and in real-world use for this goal. They are not a ranking of which peptide is better, safer, or more likely to help any individual. Fertility is intensely personal, shaped by the specific reason for difficulty conceiving, health history, and whether someone is pursuing natural conception or assisted reproduction. Use the entries below to understand the field, then take that picture somewhere it can be personalized.

1. Kisspeptin: The Most Discussed Emerging Fertility Compound

Kisspeptin has dominated fertility-focused peptide conversations in biohacking and research communities since roughly 2023, and there are real reasons for that attention. It sits at a genuinely interesting position: clinical trial data exists, the mechanism is well-mapped, and it has moved through Phase 2 trials in Europe. At the same time, it is not FDA-approved for fertility, it is not available through standard telemedicine for this indication, and community use of it runs considerably ahead of the controlled evidence.

The mechanism is one of the clearest in reproductive biology. Kisspeptin binds to a receptor called KISS1R on neurons in the hypothalamus, the brain region that governs reproductive signaling. That binding activates a cascade that ultimately causes the neuron to fire and release GnRH, which is gonadotropin-releasing hormone, the master signal that tells the pituitary to release LH and FSH. LH and FSH are the downstream hormones that drive ovulation in women and testosterone and sperm production in men. Think of kisspeptin as the switch that has to flip before the rest of the reproductive axis can run.

In clinical research, several kisspeptin analogs including MVT-602 and KP54 have completed Phase 2 trials. A 24-woman study of MVT-602 showed consistent ovulation induction with no reported side effects. Research at Imperial College London has raised the possibility that kisspeptin could induce a more physiologically natural LH surge than the standard clinical trigger, hCG, potentially reducing the risk of ovarian hyperstimulation syndrome in IVF patients. That advantage has not yet been confirmed in large comparative trials.

In community use, the shorter 10-amino acid isoform known as Kisspeptin-10 is the most discussed variant. User accounts include one report of sperm count recovering from zero after testosterone suppression, with a successful conception following roughly six months of use. Community-reported side effects are also real: severe sleep disruption, emotional instability, and elevated estradiol requiring additional medication have all been mentioned in forum threads. A physician commenting in one of the main forum discussions described kisspeptin as a genuinely promising research area while noting that definitive proof of effectiveness is not yet in hand. That characterization holds as of 2026.

2. Gonadorelin: The Clinically Established HPG Axis Stimulator

Gonadorelin is the synthetic form of GnRH, the signal the hypothalamus sends to the pituitary to trigger the release of LH and FSH. Where kisspeptin acts upstream of GnRH neurons, gonadorelin is GnRH itself, delivered directly. It has been used in fertility medicine for decades and remains a standard tool in reproductive endocrinology.

The primary fertility use of gonadorelin is pulse therapy for women with hypothalamic amenorrhea, a condition where the hypothalamus has stopped sending GnRH signals reliably. Delivering gonadorelin in a pulsatile pattern mimics the natural rhythm the hypothalamus would produce if functioning normally, which drives the pituitary to release LH and FSH and ultimately supports follicle development and ovulation. Published clinical data shows ovulation rates of roughly 96% and pregnancy rates around 80% in appropriate patient populations using pulse therapy. Those figures reflect a compound that has been refined in clinical settings over many years.

Gonadorelin is available by prescription and is standard in fertility clinics. It also appears in biohacker and peptide communities, typically in discussions about recovering hypothalamic-pituitary-gonadal axis function after testosterone use. Community users note its role as a tool for stimulating the brain-level hormone cascade rather than acting at the gonadal level directly. The evidence for its primary clinical indication is the most established of any compound in this guide. Outside that specific context, or without the medical supervision pulse therapy requires, the picture is less defined.

3. FEE Peptide: The Strongest Emerging Research Compound

The FEE peptide, also called cFEE or Fertiline, is not well known in community peptide discussions, but it has arguably the most rigorous emerging evidence of any new fertility-focused compound as of 2026. It comes out of roughly 30 years of research at Institut Cochin in France and is currently enrolled in a Phase 3 trial.

Where most fertility peptides influence hormone signals that drive ovulation or sperm production, the FEE peptide works at the cellular level inside the ovary itself. It improves the maturation of oocytes, which are the egg cells, by modulating signaling pathways inside those cells and the surrounding cumulus cells that support them. It also appears to reduce chromosomal abnormalities during egg development, which is one of the primary reasons IVF cycles fail, particularly in older patients.

Preliminary clinical data from a 66-couple trial showed a 7% increase in live births overall, with a 13% increase in the highest-prognosis group. Oocyte maturation rates improved by 30% across more than 1,600 eggs assessed. A Phase 3 trial enrolling 360 couples is underway, with results expected in 2025. If those results hold, the FEE peptide would represent a meaningful advance in IVF success rates.

This compound is not available outside clinical research settings. It is investigational and not yet approved anywhere. It earns a slot here because it carries the strongest ongoing human trial data of any emerging fertility peptide, and because reproductive medicine researchers and IVF specialists are actively watching it. For anyone in or considering an IVF cycle, knowing this compound is in late-stage trials is useful context.

4. Opiorphin: A Male Fertility Compound With Real Pilot Data

Opiorphin is a peptide found naturally in human seminal plasma, which means it already has a biological role in the male reproductive environment. Researchers identified it as an inhibitor of specific enzymes, NEP and APN, that would otherwise break down certain signaling molecules called enkephalins. In male fertility contexts, preserving enkephalin activity in seminal plasma appears to support sperm motility.

A pilot human study reported roughly an 87% increase in sperm motility in men with asthenozoospermia, the clinical term for poor sperm movement, along with a 120% improvement in forward progression in patients who responded to the compound. The honest framing is that this was a small pilot study and not a large randomized controlled trial, so the findings are preliminary. They are also human findings rather than animal data, which places opiorphin in a more meaningful evidence category than many compounds in community fertility discussions.

Opiorphin is investigational and not available outside research contexts. It does not appear widely in community peptide forums, likely because it is relatively new to researchers and even newer to the biohacking world. It earns its place here because the human study data is real, the mechanism is directly tied to sperm function, and it takes a different approach from every other compound on this list: it addresses sperm motility through the seminal plasma environment rather than through the hormonal axis.

5. SS-31: Mitochondrial Support for Egg and Sperm Quality

SS-31, also called Elamipretide, works at a different level than the other compounds here. Rather than influencing hormone signals or cell-level maturation processes, SS-31 targets the mitochondria, the structures inside cells responsible for producing energy. It does this by binding to cardiolipin, a molecule on the inner mitochondrial membrane, which protects mitochondrial function and reduces oxidative damage at the cellular level.

The fertility rationale is grounded in cell biology. Egg cells are metabolically demanding structures that depend heavily on mitochondrial function. When mitochondria are impaired by oxidative stress, which increases with age, egg quality declines and chromosomal abnormalities become more common. Sperm motility is similarly tied to mitochondrial energy production. SS-31 is used in fertility contexts as an attempt to improve the mitochondrial environment inside both eggs and sperm before and during an IVF cycle.

The evidence for the fertility application specifically comes primarily from animal studies. Some clinical data on SS-31 exists from trials for other conditions, but direct human fertility trial data is limited. In IVF-focused community discussions, users report that some reproductive endocrinologists recommend it for patients with poor egg quality and diminished ovarian reserve. It is described in community forums as potentially outperforming standard coenzyme Q10 supplementation for mitochondrial support. That characterization is user-reported and has not been confirmed in comparative human trials.

SS-31 is an experimental compound not approved by the FDA for fertility or any general consumer application. It earns a spot here because it is genuinely used and discussed in the IVF community, particularly among physicians treating difficult diminished ovarian reserve cases, and because the mitochondrial mechanism is scientifically coherent for the claimed use.

6. Sermorelin: Off-Label Hormonal Support via the GH Pathway

Sermorelin is a synthetic analog of growth hormone-releasing hormone. Rather than introducing growth hormone directly, it signals the pituitary to produce more of its own. As growth hormone rises, the liver responds by producing more IGF-1, which is insulin-like growth factor 1, a downstream molecule that plays a supporting role in follicle development and granulosa cell function inside the ovary.

The fertility rationale for Sermorelin is indirect. It does not act on the reproductive axis the way gonadorelin or kisspeptin does. The logic is that women with documented low IGF-1 levels and compromised ovarian reserve may have some of that deficit linked to suboptimal growth hormone signaling, and that restoring that signaling could support ovarian function at the margin. Some functional medicine and telemedicine providers have incorporated Sermorelin into fertility optimization protocols on this basis.

Sermorelin is FDA-approved for growth hormone deficiency in children. Compounded versions are available through 503A compounding pharmacies and are sometimes prescribed off-label by physicians for fertility support. The evidence for that specific fertility application is weak. The benefit is theoretical and built on the known role of IGF-1 in ovarian biology rather than on controlled trials showing improved fertility outcomes with Sermorelin specifically. Some practitioners use it off-label under supervision, particularly when IGF-1 levels are measurably low. Without that documented hormonal context, the rationale becomes thinner.

It earns a slot here because it is actively used and discussed in functional medicine fertility protocols, because it has a logical mechanistic connection to ovarian function, and because its availability through legitimate compounding channels places it in a different category from purely research-grade compounds.

7. Epithalon: Antioxidant Support With Mostly Anecdotal Fertility Claims

Epithalon is a synthetic tetrapeptide originally derived from research on the pineal gland. It has attracted attention in longevity and biohacking communities for its claimed effects on telomerase activation and antioxidant activity, and some of those discussions have extended into fertility contexts. The claimed fertility mechanism involves antioxidant protection of eggs and sperm and potential normalization of hormonal cycles, partly through effects on melatonin production.

No clinical trials have been conducted specifically for human fertility outcomes with Epithalon as of 2026. The available evidence consists of animal studies and in vitro work on its antioxidant and melatonin-related properties, along with community reporting from natural health and biohacking circles. It is included here because it is genuinely discussed in fertility-focused biohacking communities and because people actively seeking fertility peptides will encounter it. The honest characterization is that its fertility claims are based on plausible mechanisms and anecdotal reports rather than clinical data. Anyone considering it should understand that distinction clearly before deciding.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved specifically for fertility?

No peptide is currently FDA-approved specifically for treating infertility as of 2026. Gonadorelin and Cetrorelix are FDA-approved compounds used within clinical fertility protocols, and hCG is approved as an ovulation trigger, but none carry a direct infertility treatment indication. Compounds like Kisspeptin and the FEE peptide are in active clinical trials. Research-grade compounds including Epithalon, SS-31, and MOTS-c are not approved for any use.

Do these peptides work differently for male and female fertility?

Yes, the mechanisms and relevant compounds differ substantially by sex. Gonadorelin and Kisspeptin act on the same central hormonal pathway in both men and women, but the downstream effects differ: in women they drive follicle development and ovulation, in men they support testosterone production and sperm development. Compounds like Opiorphin and SS-31 are specifically relevant to sperm biology, while the FEE peptide addresses egg maturation and applies to female fertility in the IVF context. Choosing a compound without understanding which biological process you are trying to support is one of the most common mismatches in community fertility peptide use.

Is it safe to use these peptides while trying to conceive?

Safety profiles vary enormously across this group, and for most of these compounds, long-term safety data in preconception and pregnancy contexts simply does not exist. Compounds used within supervised clinical fertility protocols, like gonadorelin, have established safety records in that context. Research-grade compounds like SS-31, Epithalon, and Kisspeptin have limited or no safety data specific to preconception use, and community-reported side effects including hormonal disruption have been noted. Any peptide use during the period of trying to conceive warrants a conversation with a reproductive endocrinologist or qualified healthcare provider.

How does kisspeptin compare to standard hCG as an ovulation trigger?

Based on current Phase 2 data, kisspeptin analogs can induce ovulation, and researchers have proposed that the LH surge they produce may more closely resemble the natural hormonal pattern than hCG does. This is potentially relevant because a more physiologic surge could reduce the risk of ovarian hyperstimulation syndrome, a serious complication in IVF. Kisspeptin has not been proven superior to hCG in large comparative trials as of 2026, and it remains investigational while hCG is an established clinical standard.

Can these peptides be accessed through telemedicine?

It depends on the compound. Sermorelin can be accessed through 503A compounding pharmacies with a prescription, and some functional medicine providers include it in fertility optimization protocols. Gonadorelin is available by prescription through standard medical channels. Research compounds including Kisspeptin-10, SS-31, and Epithalon are not available through legitimate telemedicine for fertility purposes. They circulate primarily through research chemical channels, which carry real risks related to product purity and the absence of regulatory oversight. A telemedicine provider claiming to prescribe research-grade peptides for fertility treatment should be approached with significant caution.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for fertility support in one place.